Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-877 in severe hypertriglyceridemia with renal impairment
NCT03011450Phase 3Completed
- Start
- Nov 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of pemafibrate in hypertriglyceridemia (4 arms). Primary endpoint: Percent Change in Fasting Triglycerides at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
pemafibrate
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT03011450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011450.